OBD appoints Iain McInnes to Advisory Board
30 October 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
OBD to appoint Professor Iain McInnes to its Scientific Advisory Board
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces the appointment of Professor Iain McInnes to its Scientific Advisory Board. Iain will apply his expertise and insight as the Company's EpiSwitch™ technology continues to be adopted by leading pharmaceutical and biotechnology companies.
Iain is currently the Director of the Institute of Infection, Immunity, and Inflammation, Muirhead Professor of Medicine and Professor of Rheumatology at the University of Glasgow. Iain is the President of the European League against Rheumatism (EULAR). In May of this year, he was recipient of The Carol Nachman prize for rheumatology. 1 In December 2018, Iain was awarded a CBE for his services to medicine. 2 Oxford BioDynamics has collaborated with Professor McInnes and his teams on several successful research projects since 2014.
Professor McInnes joins Professor Karol Sikora, Professor Jane Mellor and Professor Lucien Peng-Jin Ooi on OBD's expanding Scientific Advisory Board.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:
"We are delighted to announce the appointment of Professor Iain McInnes and to welcome him to the OBD team. Iain is an eminent professor and an expert in inflammatory disease processes, a core focus for us. His knowledge and experience will be hugely beneficial, as we further collaborate with leading pharma, biotech and research institutions."
Professor Iain McInnes, member of the Scientific Advisory Board, commented:
"I have known OBD for many years now and am extremely impressed with the predictive power of EpiSwitch™ to identify patients with rheumatoid arthritis who would not respond adequately to methotrexate, the anchor drug used in this disease. OBD's method of stratifying patients could have a profound effect on clinical practice in many disease areas therefore I am looking forward to working closely with my Board colleagues and the OBD team to help realise the full potential of the EpiSwitch™ platform."
For further details please contact:
|
Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO
|
+44 (0)1865 518910 |
|
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins |
+44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 2 days ago City of London Investment Group
- 2 days ago Aberdeen Group plc
- 2 days ago NATWEST GROUP
- 2 days ago Ondo Insurtech
- 2 days ago Banco Santander S.A.